ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RGEN vs PCVX // FORWARD P/E MULTIPLE

Repligen Corporation (NASDAQ) VS. Vaxcyte Inc. (NASDAQ) • 15-METRIC TALLY: RGEN 6 — PCVX 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. PCVX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RGEN PCVX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.20% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 2.30% -27.60% +29.90 RGEN /roic <GO>
EV/EBITDA & P/E Valuation 95.0x — — TIE /valuation <GO>
Free Cash Flow Yield 0.88% -6.79% +7.67 RGEN /fcf-yield <GO>
Operating Margin 1.80% -33.50% +35.30 RGEN /operating-margins <GO>
Net Profit Margin 1.60% 0.00% +1.60 RGEN /net-margins <GO>
Revenue Growth (YoY) -3.30% 19.80% -23.10 PCVX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 9.31 18.11 -8.80 PCVX /balance-sheet <GO>
Piotroski F-Score Quality 8/9 4/9 +4.00 RGEN /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.0 48.7 -0.70 PCVX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.04 1.07 -0.03 PCVX /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $10.03B $9.76B $268.3M RGEN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RGEN REV PCVX REV RGEN GROSS % PCVX GROSS % RGEN FCF PCVX FCF
FY 2025 $0 $0 — — $93.9M -$669.3M
FY 2024 $0 $0 — — $149.7M -$475.1M
FY 2023 $0 $0 — — $113.9M -$296.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
PCVX // BETA 1.07